Literature DB >> 34306366

Clinical significance of combined detection of anti-Mullerian hormone and follicular output rate in women of late reproductive age.

Hui Su1, Lili Zuo2, Yangyang Wu3, Lisong Niu4, Yan Wu5, Hairu Sun1.   

Abstract

OBJECTIVE: This study was designed to explore the clinical significance of anti-Mullerian hormone (AMH) combined with follicular output rate (FORT) in women of late reproductive age.
METHODS: A total of 258 women (age range: 35-45 years old) who underwent pre-pregnancy examination in our hospital were collected as the research group (RG), among whom 184 were treated with in vitro fertilization-embryo transfer (IVF-ET). Concurrently, 126 women aged 24-30 years who came to our hospital for pre-pregnancy examination were enrolled as the control group (CG). AMH and FORT were detected and compared between the two groups to analyze the clinical significance of the two in women of late reproductive age.
RESULTS: Compared with the CG, AMH was decreased statistically in the RG (P<0.05). AMH was statistically higher in the regular menstrual group than in the menstrual disorder group (P<0.05), and FORT was statistically higher in the pregnancy group in comparison with the non-pregnancy group (P<0.05). AMH decreased with age (P<0.05), while FORT did not correlate with any notable difference among the three subgroups (P>0.05). High, medium and low AMH groups showed no significant difference in the number of retrieved oocytes and transplantable embryos, as well as FORT (P<0.05). A lower AMH level, was correlated with fewer number of retrieved oocytes and transplantable embryos, and higher the FORT level. Significant differences were present among the high, middle and low FORT groups regarding the number of retrieved oocytes and transplantable embryos, the clinical pregnancy rate and AMH level (P<0.05). The lower the level of FORT was, the less the number of retrieved oocytes and transplantable embryos was, the lower clinical pregnancy rate was, and the higher the AMH level was.
CONCLUSIONS: AMH decreases gradually in women with an increase of age, and FORT can effectively predict pregnancy outcome. AMH detection combined FORT is of great significance in predicting the ovarian reserve function in women of late reproductive age. AJTR
Copyright © 2021.

Entities:  

Keywords:  AMH; FORT; ovarian reserve function; women of late reproductive age

Year:  2021        PMID: 34306366      PMCID: PMC8290787     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  24 in total

1.  Follicular output rate can predict clinical pregnancy in women with unexplained infertility undergoing IVF/ICSI: a prospective cohort study.

Authors:  A Hassan; M Kotb; A AwadAllah; A Wahba; N Shehata
Journal:  Reprod Biomed Online       Date:  2017-03-16       Impact factor: 3.828

2.  The impact of peak estradiol during controlled ovarian stimulation on the cumulative live birth rate of IVF/ICSI in non-PCOS patients.

Authors:  Wanlin Zhang; Ying Tian; Duo Xie; Ye Miao; Jin Liu; Xiaohong Wang
Journal:  J Assist Reprod Genet       Date:  2019-09-04       Impact factor: 3.412

3.  Low antimüllerian hormone (AMH) is associated with decreased live birth after in vitro fertilization when follicle-stimulating hormone and AMH are discordant.

Authors:  Sarah Ligon; Michael Lustik; Gary Levy; Bruce Pier
Journal:  Fertil Steril       Date:  2019-05-02       Impact factor: 7.329

4.  Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome.

Authors:  Osman Evliyaoglu; Mathias Imöhl; Ralf Weiskirchen; Josef van Helden
Journal:  Clin Chem Lab Med       Date:  2020-07-28       Impact factor: 3.694

Review 5.  The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling.

Authors:  Fie Pilsgaard; Anna G-A Grynnerup; Kristine Løssl; Leif Bungum; Anja Pinborg
Journal:  Acta Obstet Gynecol Scand       Date:  2018-03-30       Impact factor: 3.636

6.  Correlation of Serum Anti-Mullerian Hormone with Ovarian Follicle Output Rate in Infertile Females: A Clomiphene Citrate Challenge Test.

Authors:  Syeda Fatima; Qanbar Naqvi; Ambreen Tauseef; Mehwish Qamar; Qudsia U Khan; Tanzeela Akram; Muniza Saeed
Journal:  Cureus       Date:  2020-05-08

7.  Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome.

Authors:  Ali Abbara; Pei Chia Eng; Maria Phylactou; Sophie A Clarke; Tia Hunjan; Rachel Roberts; Sunitha Vimalesvaran; George Christopoulos; Rumana Islam; Kate Purugganan; Alexander N Comninos; Geoffrey H Trew; Rehan Salim; Artsiom Hramyka; Lisa Owens; Tom Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-26       Impact factor: 5.555

8.  Regulation of AMH, AMHR-II, and BMPs (2,6) Genes of Bovine Granulosa Cells Treated with Exogenous FSH and Their Association with Protein Hormones.

Authors:  Saqib Umer; Abdul Sammad; Huiying Zou; Adnan Khan; Bahlibi Weldegebriall Sahlu; Haisheng Hao; Xueming Zhao; Yachun Wang; Shanjiang Zhao; Huabin Zhu
Journal:  Genes (Basel)       Date:  2019-12-12       Impact factor: 4.096

9.  Mutational Analysis of the Putative Anti-Müllerian Hormone (AMH) Binding Interface on its Type II Receptor, AMHR2.

Authors:  Kaitlin N Hart; David Pépin; Magdalena Czepnik; Patricia K Donahoe; Thomas B Thompson
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

10.  Follicular output rate tends to improve clinical pregnancy outcomes in patients with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer treatment.

Authors:  Xiaoqing Tan; Yu Wen; Huixiao Chen; Ling Zhang; Bin Wang; Hongwei Wen; Fengli Zhang; Qin Wu; Jing Du
Journal:  J Int Med Res       Date:  2019-08-04       Impact factor: 1.671

View more
  1 in total

1.  Nomogram based on clinical and laboratory characteristics of euploid embryos using the data in PGT-A: a euploid-prediction model.

Authors:  Xitong Liu
Journal:  BMC Pregnancy Childbirth       Date:  2022-03-17       Impact factor: 3.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.